Researchers from the University of Texas MD Anderson Cancer Center who analyzed data on 973 pancreatic cancer patients (259 of whom were diabetic) and 863 non-cancer patients (109 of whom were diabetic) found that the risk of patients who had ever taken metformin in developing pancreatic cancer was reduced by 60 percent, compared to those who had never taken the drug. According to the study published in the August issue of Gastroenterology, the risk reduction was particularly apparent among diabetics who had taken metformin for five years or more.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지